Page 295 - Binder2

Case 2: An Immunocompromised Adult Who Tolerized
After Rejection

In another early access case, an adult with a chronic
autoimmune condition had cycled through multiple
biologics—each promising relief, each eventually failing.
The problem wasn’t lack of efficacy. It was immune
rejection. The patient developed anti-drug antibodies
(ADAs) that neutralized the injected therapies, rendering
them useless and triggering allergic reactions.

Rather than escalate to stronger immunosuppressants, the
clinical team tried something different: a plant-made oral
version of the same therapeutic protein. Low-dose, gut-
delivered, and embedded in plant tissue, the drug was
introduced not as a threat, but as a familiar visitor.

The result? Tolerization.

The patient’s immune system stopped treating the protein
as foreign. ADA levels dropped. Clinical symptoms
improved. The therapy that had once triggered rejection
became, in a new form, something the body could accept.

This wasn’t just drug delivery. It was immune retraining.

Case 3: Plant-Derived IgA for Enteric Infections

In settings like disaster zones, refugee camps, and
international travel, the risk of diarrheal disease is high—
and access to safe, fast-acting prophylactics is low.
Antibiotics can disrupt the microbiome. Vaccines may not

293